ProCE Banner Activity

Phase I Trial: Updated Analysis of BCMA x CD3 Bispecific Antibody Teclistamab (JNJ-64007957) in Patients With R/R MM

Slideset Download
Conference Coverage

Subcutaneous administration of teclistamab (JNJ-64007957) was well tolerated and associated with high response rates at the RP2D in an ongoing phase I trial of heavily pretreated patients with multiple myeloma.

Released: December 08, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology